Drug Trial Radar · NCT02496208
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
152
Planned (sponsor's estimate)
Start
Jul 22, 2015
Primary completion
Jul 30, 2027
Study completion Jul 30, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jul 14, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial studies the side effects and best doses of cabozantinib s-malate and nivolumab with or without ipilimumab in treating patients with genitourinary (genital and urinary organ) tumors that have spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving cabozantinib s-malate and nivolumab alone or with ipilimumab works better in treating patients with genitourinary tumors.
Conditions
- Bladder Small Cell Neuroendocrine Carcinoma
- Bladder Squamous Cell Carcinoma
- Bladder Urothelial Carcinoma
- Clear Cell Renal Cell Carcinoma
- Invasive Bladder Plasmacytoid Urothelial Carcinoma
- Invasive Bladder Sarcomatoid Urothelial Carcinoma
- Invasive Sarcomatoid Urothelial Carcinoma
- Kidney Medullary Carcinoma
- Malignant Genitourinary System Neoplasm
- Malignant Solid Neoplasm
- Penile Carcinoma
- Penile Squamous Cell Carcinoma
- Renal Cell Carcinoma
- Renal Pelvis Urothelial Carcinoma
- Sarcomatoid Renal Cell Carcinoma
- Stage III Bladder Cancer AJCC v8
- Stage III Penile Cancer AJCC v8
- Stage III Renal Cell Cancer AJCC v8
- Stage III Renal Pelvis and Ureter Cancer AJCC v8
- Stage III Renal Pelvis Cancer AJCC v8
- Stage III Ureter Cancer AJCC v8
- Stage III Urethral Cancer AJCC v8
- Stage IV Bladder Cancer AJCC v8
- Stage IV Penile Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
- Stage IV Renal Pelvis and Ureter Cancer AJCC v8
- Stage IV Ureter Cancer AJCC v8
- Stage IV Urethral Cancer AJCC v8
- Ureter Urothelial Carcinoma
- Urethral Urothelial Carcinoma
Interventions
Biopsy ProcedureProcedure
Undergo biopsies
Biospecimen CollectionProcedure
Undergo collection of blood
Cabozantinib S-malateDrug
Given PO
Computed TomographyProcedure
Undergo CT scan
Echocardiography TestProcedure
Undergo echocardiography
IpilimumabBiological
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
NivolumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended phase II dose (Phase I)Time frame: Up to 4-6 weeks
- Incidence of adverse events (Phase I)Time frame: Up to 30 days post treatment
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California
Los Angeles General Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
National Institutes of Health Clinical Center
Bethesda, Maryland
NCI - Center for Cancer Research
Bethesda, Maryland
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.